Replies to post #17681 on Momenta Pharmaceuticals, Inc. (MNTA)

[DewDiligence]

...Amgen didn't try to circumvent Humira formulation patents.

The question is whether AMGN didn't try... or whether AMGN simply didn't know how to do it in a manner that preserved biosimilarity. I lean toward the later interpretation.